Caris Life Sciences, Inc. (CAI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 294 | - | 258 | 306 | 412 | 812 | 990 | 1,030 |
| Operating profit | $m | 45 | 153 | ||||||
| Net profit | $m | 28 | - | -321 | -341 | -282 | -538 | - | 35 |
| EPS reported | $ | -1.86 | 0.37 | ||||||
| Operating cashflow per share | $ | 0.29 | 0.71 | ||||||
| Capex per share | $ | 0.06 | 0.19 | ||||||
| FCF per share | $ | 0.24 | 0.52 | ||||||
| Free cash flow | $m | 67 | 146 | ||||||
| Net debt | $m | -421 | -341 | ||||||
| Book value equity | $m | 577 | 592 | ||||||
| Book value per share | $ | 1.99 | 2.09 | ||||||
| Number of shares | m | 289.89 | 282.89 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 89.35 | ||||||
| P/B LTM | x | 13.19 | 12.87 | ||||||
| P/S LTM | x | 9.38 | 7.70 | ||||||
| P/FCF LTM | x | 113.87 | 52.00 | ||||||
| EV/EBITDA LTM | x | 632.55 | 41.68 | ||||||
| EV/Sales LTM | x | 8.86 | 6.92 | ||||||
| Earnings Yield LTM | % | -7.06% | +1.12% | ||||||
| FCF Yield | % | +0.88% | +1.92% | ||||||
| Quality | |||||||||
| ROE | % | -93.18% | +18.77% | ||||||
| ROIC | % | +4.52% | +14.67% | ||||||
| Operating margin | % | +5.56% | +15.49% | ||||||
| Gross margin | % | +66.40% | +69.66% | ||||||
| FCF/Sales | % | +8.24% | +14.80% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +96.97% | +140.04% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.18 | 0.32 | ||||||
| Net Debt/EBITDA | x | -36.80 | -1.38 | ||||||
| EBIT/Net interest | x | 0.79 | 3.27 | ||||||
| Net debt/market cap | % | +4.98% | +5.55% | ||||||
| Net debt/Equity | x | -0.73 | -0.58 | ||||||
| Gross debt/equity | x | 0.66 | 0.76 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free